Literature DB >> 29876877

Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in 'Rich' Countries?

Alan Haycox1.   

Abstract

Mesh：

Year:  2018        PMID： 29876877     DOI： 10.1007/s40273-018-0666-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  2 in total

1.  Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective.

Authors:  Kenneth Boyd; Peter Hall
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

2.  The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

Authors:  Tanja Novakovic; Antony P Martin; Mark Parker; Alessandra Ferrario; Simo Vukovic; Krzysztof Łanda; Jaroslav Duba; Dávid Dankó; Nikolaos Kotsopoulos; Brian Godman; Jelena Ristic; Danka Stefanovic; Danka Tesic
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2017-10-09       Impact factor: 2.217
  2 in total
  1 in total

Review 1.  Improving WHO's understanding of WHO guideline uptake and use in Member States: a scoping review.

Authors:  Kiran Saluja; K Srikanth Reddy; Qi Wang; Ying Zhu; Yanfei Li; Xiajing Chu; Rui Li; Liangying Hou; Tanya Horsley; Fred Carden; Kidist Bartolomeos; Janet Hatcher Roberts
Journal:  Health Res Policy Syst       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.